Verastem (VSTM) BidaskScore is increased to Sold

Verastem

The BidaskScore of Verastem VSTMVSTM shows that the shares of the company are now VSTMStrongly Bought Sold by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Held since March 5.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Verastemˌ Inc. is a clinical biopharmaceutical companyˌ which is focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. The company is developing small molecule inhibitors of signaling pathways which includes Focal Adhesion Kinase FAKˌ PI3K/mTOR and Wnt that are critical to cancer stem cell survival and proliferation. Verastem was founded by Richard H. Aldrichˌ Michelle Dippˌ Piyush Guptaˌ Satish Jindalˌ Eric S. Landerˌ Robert F. Weinberg and Christoph H. Westphal on August 4ˌ 2010 and is headquartered in Cambridgeˌ MA.

Verastem

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.